Please login to the form below

Not currently logged in

Novartis agrees to help produce Roche’s repurposed COVID-19 drug

Novartis will make ingredients for Actemra/RoActemra, which is being investigated in COVID-19

Novartis has signed an initial agreement with Roche to help produce its repurposed COVID-19 treatment Actemra/RoActemra.

Actemra/RoActemra (tocilizumab) is already approved to treat a number of inflammatory conditions, including rheumatoid arthritis, paediatric juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, giant cell arteritis and CAR-T cell-induced cytokine release syndrome.

During the COVID-19 pandemic, Roche repurposed the drug to evaluate its potential benefit against the novel virus.

Earlier this year, the UK-based RECOVERY trial found that Roche’s anti-inflammatory drug reduced the risk of death in patients hospitalised with COVID-19

Tocilizumab was found to reduce the relative risk of death by 14% when used alongside the steroid medication dexamethasone in COVID-19 patients requiring oxygen in the RECOVERY trial.

Researchers discovered that 29% of patients in the tocilizumab group died within 28 days compared to 33% of patients in the placebo group, which is an absolute difference of 4%.

The drug reduced the chance of death or the need for mechanical ventilation from 38% to 33%.

Treatment with tocilizumab, plus dexamethasone, also reduced the time patients spent in hospital by five days, the researchers found.

Roche will transfer the manufacturing process expertise to Novartis’ Drug Substance Singapore site during the second quarter of 2021, with the initial agreement covering the technology transfer and the process validation.

“Novartis is fully committed to collaborating with Roche in offering our proven biologics production capabilities,” said Steffen Lang, head of Novartis technical operations and member of the Novartis executive committee.

“As one of the world’s largest producers of medicines, Novartis can mobilise its manufacturing capabilities on multiple fronts,” he added.

In March, Novartis signed an initial manufacturing agreement with CureVac to help manufacture the latter’s mRNA-based COVID-19 vaccine candidate CVnCoV.

Novartis plans to manufacture the mRNA and bulk drug product for CureVac's CVnCoV of up to 50 million doses by the end of 2021, with further scale-up to 200 million doses in 2022.

Deliveries of the CVnCoV doses from Novartis’ Kundl, Austria manufacturing site are expected to begin in summer 2021.

“At the Kundl site, Novartis is a pioneer and has decades of experience in pharmaceutical production of proteins and in more recent years of nucleic acids. We are currently expanding our site with additional capacities for the production of mRNA in order to best serve the increasing demand,” commented Lang.

Article by
Lucy Parsons

15th April 2021

From: Marketing



COVID-19 Updates and Daily News

Featured jobs


Add my company

some pressure is helpful but too much of the wrong sort quickly takes its toll. we help creatove agenices manage...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....